S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61

Arix Bioscience Share Forecast, Price & News

GBX 112.25
0.00 (0.00%)
(As of 06/24/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
3,880 shs
Average Volume
155,209 shs
Market Capitalization
£145.06 million
P/E Ratio
Dividend Yield
Price Target
GBX 256
30 days | 90 days | 365 days | Advanced Chart

Receive ARIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arix Bioscience and its competitors with MarketBeat's FREE daily newsletter.

ARIX Stock Forecast (MarketRank)

Overall MarketRank

1.64 out of 5 stars

Analyst Opinion: 3.3Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
Arix Bioscience logo

About Arix Bioscience (LON:ARIX)

Arix Bioscience plc is a venture capital firm specializing in all stages of growth, seed stage, preclinical and clinical stage assets, startup, early stage, mid venture, late stage, growth capital investments as well as private and public equity. The firm seeks to invest in biotech companies, novel therapeutics, innovative technologies, medical innovation comprising healthcare and life sciences. It seeks to invest globally. The firm employs an evergreen approach to funding. It primarily makes investments from its own balance sheet. The firm prefers to take board seat. The firm exit when the optimum value has been reached. Arix Bioscience plc is formerly known as Perceptive Bioscience Investments Limited. Arix Bioscience plc was founded in 2015 and is based in London, United Kingdom.

ARIX Stock News Headlines

Unaudited NAV for May 2022
Result of Annual General Meeting 2022
How do brokers rate Arix Bioscience?
Unaudited NAV for April
Unaudited NAV and Notice of Financial Results
Director changes at ReNeuron’s board
ReNeuron unveils board reshuffle as part of business refocus
Arix Bioscience PLC: Notification of Major Share Holding
See More Headlines

Industry, Sector and Symbol

Year Founded

Company Calendar

Next Earnings (Estimated)

Price Target and Rating

Average Stock Price Forecast
GBX 256
High Stock Price Forecast
GBX 256
Low Stock Price Forecast
GBX 256
Forecasted Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
3 Analysts


Pretax Margin


Sales & Book Value

Annual Sales
£-53.58 million
Cash Flow
GBX 108.15 per share
Book Value
GBX 205.80 per share


Free Float
Market Cap
£145.06 million
Not Optionable

Arix Bioscience Frequently Asked Questions

Should I buy or sell Arix Bioscience stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arix Bioscience in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" Arix Bioscience stock.
View analyst ratings for Arix Bioscience
or view top-rated stocks.

What is Arix Bioscience's stock price forecast for 2022?

3 analysts have issued 12-month price targets for Arix Bioscience's shares. Their ARIX stock forecasts range from GBX 256 to GBX 256. On average, they anticipate Arix Bioscience's share price to reach GBX 256 in the next twelve months. This suggests a possible upside of 128.1% from the stock's current price.
View analysts' price targets for Arix Bioscience
or view top-rated stocks among Wall Street analysts.

How has Arix Bioscience's stock performed in 2022?

Arix Bioscience's stock was trading at GBX 121 at the beginning of the year. Since then, ARIX shares have decreased by 7.2% and is now trading at GBX 112.25.
View the best growth stocks for 2022 here

When is Arix Bioscience's next earnings date?

Arix Bioscience is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022.
View our earnings forecast for Arix Bioscience

Who are Arix Bioscience's key executives?

Arix Bioscience's management team includes the following people:
  • Mr. Robert Lyne, CEO, Gen. Counsel, Company Sec. & Director
  • Ms. Nikki Edgar, Head of Fin.
  • Mr. Mark Chin M.B.A., M.S., Managing Director (Age 40)

What is Arix Bioscience's stock symbol?

Arix Bioscience trades on the London Stock Exchange (LON) under the ticker symbol "ARIX."

How do I buy shares of Arix Bioscience?

Shares of ARIX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Arix Bioscience's stock price today?

One share of ARIX stock can currently be purchased for approximately GBX 112.25.

How much money does Arix Bioscience make?

Arix Bioscience (LON:ARIX) has a market capitalization of £145.06 million and generates £-53.58 million in revenue each year.

How many employees does Arix Bioscience have?

Arix Bioscience employs 12 workers across the globe.

How can I contact Arix Bioscience?

Arix Bioscience's mailing address is 20 Berkeley Square, LONDON, W1J 6EQ, United Kingdom. The official website for Arix Bioscience is arixbioscience.com. The company can be reached via phone at +44-20-72901050.

This page (LON:ARIX) was last updated on 6/26/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.